Commerzbank Aktiengesellschaft Nektar Therapeutics Transaction History

Commerzbank Aktiengesellschaft

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2020 Jul 21, 2020	SELL	$16.86 - $23.44 $349,811 - $486,333	-20,748 Closed	0 $0
Q1 2020 Apr 29, 2020	SELL	$14.47 - $27.96 $605,149 - $1.17 Million	-41,821 Reduced 66.84%	20,748 $370,000
Q4 2019 Jan 17, 2020	BUY	$15.87 - $23.12 $97,806 - $142,488	6,163 Added 10.93%	62,569 $1.35 Million
Q3 2019 Oct 17, 2019	BUY	$16.91 - $36.27 $503,021 - $1.08 Million	29,747 Added 111.58%	56,406 $1.03 Million
Q2 2019 Jul 23, 2019	BUY	$31.0 - $36.3 $826,429 - $967,721	26,659 New	26,659 $949,000

128

111M

150K

Ticker NKTR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 187,404,992
Market Cap $231M
Description
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, re...

Get notified when there are updates to the investment portfolio of Commerzbank Aktiengesellschaft , based on Form 13F filings with the SEC.

Stay updated on Commerzbank Aktiengesellschaft with notifications on news.